Allogeneic host peptide–Human Leukocyte Antigen complex (pHLA complex)

Allogeneic host peptide–Human Leukocyte Antigen (HLA) complexes are molecular structures formed by the association of host-derived peptides with HLA molecules on the surface of recipient cells. These complexes are central to the immune response in allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation. In HSCT, donor T cells recognize these complexes as foreign due to genetic polymorphisms, leading to the activation of an immune cascade. This recognition is the primary cause of Graft-versus-Host Disease (GvHD), where donor cells attack host tissues such as the skin, liver, and gastrointestinal tract (Ferrara et al., 2009). Conversely, the recognition of these complexes on malignant cells mediates the Graft-versus-leukemia (GvL) effect, which is crucial for preventing cancer recurrence (Bleakley & Riddell, 2004). Pharmacological intervention typically involves immunosuppressive drugs like tacrolimus or cyclosporine that inhibit the T-cell signaling pathways initiated by the recognition of these complexes. Advanced therapeutic approaches are exploring the use of TCR-like antibodies or engineered T cells to specifically target minor histocompatibility antigens presented by these complexes to minimize toxicity (Warren et al., 1998).

Other names

Allo-HLAAllogeneic MHC-peptide complexMinor histocompatibility antigen complexmHAg-HLA complexHost-derived peptide-MHC complex

Inhibition of T-cell receptor (TCR) signaling and downstream cytokine production following recognition of allogeneic peptide-HLA complexes; depletion of alloreactive T cells; blockade of costimulatory pathways.